

IPAR



Publicly Available Assessment Report for a **Veterinary Medicinal Product**

Neopen Suspension for Injection

PRODUCT SUMMARY

Name, strength and pharmaceutical form	Neopen Suspension for Injection
Active substance	Procaine Benzylpenicillin 200 mg, Neomycin sulphate 100 mg
Marketing Authorisation Holder	Intervet Ireland Limited
Date of Authorisation	1st October 2002
Target species	Cattle, pigs and horses
Indication for use	<p>For the treatment of infections caused by organisms which are susceptible to neomycin/penicillin combinations:</p> <p>In pigs and cattle, including pasteurellosis, mastitis, metritis, enteric and urinary tract infections. Sensitive organisms include: Streptococci, Staphylococcus spp, some E Coli and some Salmonella spp.</p> <p>In horses, especially those infections associated with Streptococci and Staphylococci.</p>
ATCvet code	QJ01RA01 Penicillins, combinations with other antibacterials

PUBLIC ASSESSMENT REPORT

The public assessment report reflects the scientific conclusion reached by the HPRA at the end of the evaluation process and provides a summary of the grounds for approval of the marketing authorisation for the specific veterinary medicinal product. It is made available by the HPRA for information to the public, after the deletion of commercially confidential information. The legal basis for its creation and availability is contained in Article 25.4 of EC Directive 2001/82/EC as amended by Directive 2004/28/EC for veterinary medicinal products. It is a concise document which highlights the main parts of the documentation submitted by the applicant and the scientific evaluation carried out by HPRA leading to the approval of the product for marketing in Ireland.

The Summary of Product Characteristics (SPC) for this product is available on the HPRA's website.

I SCIENTIFIC OVERVIEW

The initial application for the product was assessed before there was a requirement to have a public assessment report, therefore no details in this section are available. Please refer to Section VI for significant post-approval changes which are important for the quality, safety and efficacy of the product.

II QUALITY ASPECTS

See section I.

III SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

See section I.

IV CLINICAL ASSESSMENT (EFFICACY)

See section I.

V OVERALL CONCLUSION AND BENEFIT/RISK ASSESSMENT

On the basis of the original data submitted, the HPRA considered that the product demonstrated adequate evidence of efficacy for the approved indications as well as a satisfactory benefit/risk profile and therefore granted a marketing authorisation.

VI POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the HPRA website.

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

Quality Changes

Summary of change (Application number)

Change to product name (CRN 7021063)